Page last updated: 2024-10-26

1-phenyl-2-palmitoylamino-3-morpholino-1-propanol and Leukemia, Erythroblastic, Acute

1-phenyl-2-palmitoylamino-3-morpholino-1-propanol has been researched along with Leukemia, Erythroblastic, Acute in 1 studies

1-phenyl-2-palmitoylamino-3-morpholino-1-propanol: a sphingolipid analog; inhibits the enzyme activity in infected erythrocytes
N-[1-hydroxy-3-(morpholin-4-yl)-1-phenylpropan-2-yl]hexadecanamide : A fatty amide resulting from the formal condensation of palmitic acid with the primary amino group of 2-amino-3-(morpholin-4-yl)-1-phenylpropan-1-ol.

Leukemia, Erythroblastic, Acute: A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Liu, Y1
Xie, KM1
Yang, GQ1
Bai, XM1
Shi, YP1
Mu, HJ1
Qiao, WZ1
Zhang, B1
Xie, P1

Other Studies

1 other study available for 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol and Leukemia, Erythroblastic, Acute

ArticleYear
GCS induces multidrug resistance by regulating apoptosis-related genes in K562/AO2 cell line.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:3

    Topics: Apoptosis; bcl-2-Associated X Protein; Down-Regulation; Drug Resistance, Multiple; Drug Resistance,

2010